Human Anti-ZIKV Recombinant Antibody (clone MZ2) (CAT#: FAMAB-0745WJ)

Figure 1 MZ2 yielded nearly identical binding, affinity and neutralization potency as MZ.

b, Neutralization (FlowNT) of MZ2 against ZIKV and DENV1-4. c,d, Comparison of MZ2 and MZ4 neutralization potencies against ZIKV (Paraiba_01) (c) and DENV-2 (S16803) (d). Shown are the mean % neutralization obtained from two independent experiments with the IC50 (ng ml⁻¹) indicated in parentheses for each virus.

Dussupt, V., Sankhala, R. S., Gromowski, G. D., Donofrio, G., De La Barrera, R. A., Larocca, R. A., ... & Krebs, S. J. (2020). Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nature medicine, 26(2), 228-235.

Figure 2 MZ2 was able to protect against ZIKV and DENV-2 viremia and viral dissemination in mice.

e,f, MZ2 prevents ZIKV replication in serum (e) and tissues (f). Groups of naive recipient Balb/c mice (n = 5 per group) were treated with MZ2 (200 µg) and challenged with ZIKV. Tissues were harvested at day 3 post-challenge. Asterisks indicate significance was reached using a two-tailed Mann-Whitney t-test, P = 0.0079, n = 5 mice. Bars indicate median value. g,h, Protective effect of MZ2 in a DENV-2 mouse model. MZ2 prevents weight loss (g) and significantly reduces viral burden in (h) serum and tissues. Groups of naive Ifnar^−/− C57BL/6 mice (n = 10 per group) were treated with MZ2 (200 µg) and challenged with DENV-2. Dotted lines indicate the limit of detection of the assay, and the solid bars indicate the median DENV-2 viral burden. Asterisks indicate significance using a two-tailed Mann-Whitney t-test, P = 0.0079, n = 5 mice.

Dussupt, V., Sankhala, R. S., Gromowski, G. D., Donofrio, G., De La Barrera, R. A., Larocca, R. A., ... & Krebs, S. J. (2020). Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nature medicine, 26(2), 228-235.